In a meta-analysis involving 48 randomized controlled trials, compared with placebo or other antidiabetic drugs, SGLT2 inhibitors exerted renal protection by decreasing albuminuria, slowing the progression from microalbuminuria to macroalbuminuria, and reducing the risk of end-stage renal disease (61). This evidence concerns the gene SLC5A2 and chronic kidney disease.